Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

The difference between groups through week 26, however, did not reach statistical significance, likely because of the late time-to-flare (median 25.1 weeks) in the placebo group relative to the 26-week time point at which the assessment of cumulative prednisone dose ended.

also in 111,027 other papers